

A. JANSSENS, MD, PHD

**DEAR COLLEAGUES,**

It is already time to invite you to read issue seven of 2024 of the *Belgian Journal of Hematology* (BJH)!

For **REVIEW HEMATOLOGY** the editorial board has chosen “**Precision medicine in relapsed and refractory paediatric haematological malignancies and the role of an International Tumour Board**” by A. Reekmans *et al.* (Department of Paediatric Haematology-Oncology and Stem Cell Transplantation, Ghent University Hospital). The authors discuss the current challenges in relapsed/refractory (R/R) haematological malignancies and introduce the use of international tumour boards to help treat physicians when confronted with these difficult cases.

In **PHARMACOTHERAPY**, J. Neefs *et al.* (Department of Pharmacy, University Hospitals Leuven) summarise the mechanism of action, dosage, administration, efficacy, and tolerability of zanubrutinib, the third available covalent Bruton tyrosine kinase inhibitor in Belgium. Zanubrutinib is not only available for chronic lymphocytic leukaemia and Waldenström’s macroglobulinaemia, but for certain R/R marginal zone lymphomas as well.

In **HEMATOCASE**, the interesting case report from S. Marchetta *et al.* (Department of Cardiology, Health Group CHC-Liège) who present “**Light chains amyloidosis: Case report with special focus on cardiac involvement and literature survey**”. Although cardiac involvement is the leading cause of patient’s morbidity in Light chain amyloidosis, the authors could show that incorporating some of the new MM standards in the treatment of this disease is able to improve survival.

In **HEMATOTHESIS**, L. Smolders (Department of Haematology, University Hospitals Leuven) presents the results of her master thesis “**BALT lymphomas: A retrospective analysis at the University Hospitals Leuven**”. The conclusion of this analysis provides guidance on how to diagnose and stage this specific indolent lymphoma and which treatment options are preferred.

J. Collins (medical writer, Ariez International BV, Ghent) highlights the most important haematological topics discussed at ESMO 2024 in **CONGRESS NEWS** and J. Blokken (medical writer, Ariez International BV, Ghent) gives us an update on new reimbursements in **REIMBURSEMENT NEWS**.

Enjoy reading the latest issue,

A. Janssens, MD, PhD

Editor-in-Chief